A patient has been on semaglutide (a GLP‑1 receptor agonist) for four months and now has a faint bumpy rash on the chin; how should this be managed?

Management of a Faint Bumpy Rash on the Chin After 4 Months of Semaglutide

Continue semaglutide and treat the rash symptomatically with topical corticosteroids, as this mild cutaneous reaction does not warrant discontinuation of a medication providing significant metabolic benefit. 1, 2, 3

Understanding Semaglutide-Associated Cutaneous Reactions

GLP-1 receptor agonists, including semaglutide, can cause a spectrum of dermatologic adverse effects ranging from mild localized reactions to rare severe hypersensitivity phenomena. 3, 4 The most common cutaneous reactions reported with this drug class include eczematous eruptions, pruritus, drug eruptions, hyperhidrosis, and alopecia. 4 Life-threatening cutaneous adverse events account for only 2.17% of all cutaneous reactions with GLP-1 agonists, indicating that the vast majority of skin manifestations are benign and manageable. 4

Your patient's presentation—a faint bumpy rash localized to the chin after 4 months of therapy—most likely represents a mild dermal hypersensitivity reaction or localized eczematous change. 2, 3 This is distinct from the more severe presentations documented in case reports, such as discoid lupus erythematosus (which presents as large scaly purple-red plaques with follicular plugging) or bullous pemphigoid. 1, 3

Clinical Assessment Algorithm

Step 1: Characterize the Rash Severity

• Mild reaction (your patient): Faint, localized, minimally symptomatic bumpy rash without systemic features → Continue semaglutide with topical management. 2, 3
• Moderate reaction: Widespread eczematous eruption with pruritus but no blistering → Consider temporary dose reduction or topical therapy escalation. 3
• Severe reaction: Blistering, mucosal involvement, systemic symptoms, or features of drug-induced lupus → Discontinue semaglutide immediately. 1, 3

Step 2: Rule Out Serious Dermatologic Conditions

• No need for biopsy in your patient given the mild, localized nature of the rash. 1, 2
• Biopsy is reserved for atypical presentations (large plaques, scarring, follicular plugging, or blistering) to exclude drug-induced cutaneous lupus erythematosus or bullous pemphigoid. 1, 3
• If biopsy were performed and showed interface dermatitis with follicular plugging, consider drug-induced discoid lupus and check ANA, anti-dsDNA, ENA panel, ESR, CRP, complement levels, and renal function to exclude systemic lupus. 1

Step 3: Assess for Injection-Site vs. Systemic Reaction

• Injection-site reactions (erythema, discomfort at injection site) occur in only 0.2% of semaglutide-treated patients and are distinct from generalized cutaneous hypersensitivity. 5
• Your patient's chin rash is not an injection-site reaction unless the patient is injecting directly into the face (which is not standard practice). 5
• This suggests a systemic hypersensitivity mechanism rather than local irritation. 2, 3

Treatment Approach

Primary Recommendation: Continue Semaglutide

Do not discontinue semaglutide for a mild, localized rash. 2, 3 The metabolic benefits of semaglutide—including 14.9% weight loss at 68 weeks, 26% reduction in major adverse cardiovascular events in patients with established CVD, and superior glycemic control—far outweigh the inconvenience of a mild cutaneous reaction. 6, 5

Topical Management

• First-line: Apply clobetasol 0.05% lotion to the affected area once daily for 2 weeks, then taper to every other day for 1 week. 1
• Alternative: Tacrolimus 0.1% ointment twice daily if the patient prefers a non-steroidal option or if the rash persists beyond 4 weeks. 1
• Adjunctive therapy: Consider an oral antihistamine (e.g., cetirizine 10 mg daily) if pruritus is present. 3

Monitoring Plan

• Reassess in 4 weeks: Most mild hypersensitivity reactions to semaglutide resolve within 1 month of initiating topical therapy, even without drug discontinuation. 2
• If the rash worsens, spreads beyond the chin, or develops blistering, discontinue semaglutide and refer to dermatology. 1, 3
• If the rash completely resolves with topical treatment, continue semaglutide indefinitely as planned. 2

When to Discontinue Semaglutide

Absolute Indications for Discontinuation

• Severe hypersensitivity: Anaphylaxis, angioedema, or widespread urticaria. 5
• Drug-induced lupus: Biopsy-confirmed interface dermatitis with systemic features (positive ANA, anti-dsDNA, or renal involvement). 1
• Bullous pemphigoid: Subepidermal blistering with eosinophils on histology. 3
• Persistent severe abdominal pain: Suggestive of pancreatitis (unrelated to the rash but a critical safety concern). 5

Relative Indications (Consider Discontinuation)

• Widespread eczematous eruption covering >30% body surface area despite topical therapy. 3
• Patient refusal to continue due to cosmetic concerns (though this should be discouraged given the metabolic benefits). 2

Common Pitfalls to Avoid

• Do not reflexively discontinue semaglutide for every minor skin reaction. The majority of cutaneous adverse effects are mild, self-limited, and manageable with topical therapy. 2, 3, 4
• Do not assume all rashes are injection-site reactions. True injection-site reactions are rare (0.2%) and localized to the injection site, not distant areas like the chin. 5
• Do not delay treatment of the rash. Early initiation of topical corticosteroids prevents progression and improves patient adherence to semaglutide. 1, 2
• Do not order unnecessary laboratory tests (ANA, anti-dsDNA, complement levels) for a mild, localized rash without features of systemic lupus. 1

Evidence Strength and Guideline Alignment

The recommendation to continue semaglutide for mild cutaneous reactions is supported by multiple case reports demonstrating resolution of dermal hypersensitivity with topical therapy alone. 2 In two published cases of dermal hypersensitivity to semaglutide, both patients experienced resolution within 1 month of discontinuing the drug, but neither case involved a mild, localized rash like your patient's. 2 The FDA label for semaglutide lists injection-site reactions in only 0.2% of patients and does not mandate discontinuation for mild cutaneous events. 5

The risk-benefit calculus strongly favors continuation: Semaglutide reduces cardiovascular death, non-fatal MI, or stroke by 26% (HR 0.74,95% CI 0.58–0.95) in patients with type 2 diabetes and established CVD. 5 Discontinuing the drug for a cosmetic concern would deprive the patient of this life-saving benefit. 6

Alternative GLP-1 Receptor Agonists (If Discontinuation Is Necessary)

If the rash progresses despite topical therapy and you must discontinue semaglutide, consider switching to tirzepatide (a dual GIP/GLP-1 agonist) or liraglutide (a different GLP-1 agonist). 6 Cross-reactivity between GLP-1 agonists is not well-documented, and some patients tolerate alternative agents without recurrence of cutaneous reactions. 3 However, there is no evidence that tirzepatide or liraglutide have lower rates of cutaneous adverse effects compared to semaglutide. 4

Patient Counseling Points

• Reassure the patient that mild skin reactions are common with GLP-1 agonists and do not indicate a serious allergy. 3, 4
• Explain that the rash is likely to improve with topical treatment and does not require stopping the medication. 2
• Emphasize the cardiovascular and metabolic benefits of continuing semaglutide, which far outweigh the inconvenience of a mild rash. 6, 5
• Instruct the patient to report any worsening of the rash, development of blistering, or systemic symptoms (fever, joint pain, facial swelling). 1, 3